The Lymphoma Epidemiology of Outcomes (LEO) Study is a collaboration between 8 prominent medical centers and universities around the United States. The goal is to build a large and diverse observational cohort to support a broad research agenda aimed at identifying several factors that impact non-Hodgkin lymphoma survivorship.

We will be collecting data and samples that will help us understand the causes for different types of non-Hodgkin lymphomas, the best treatments and the best ways to help survivors. Your participation in this study is key to our success.

**GOALS**

- Support research that finds new and better ways to improve the length and quality of life of people living with non-Hodgkin lymphoma
- Create a long-term cohort registry of over 12,000 newly diagnosed non-Hodgkin lymphoma patients
- Create a bank of blood and tissue specimens
- Collect clinical and risk factor data from participants at enrollment and over time.
- Follow patients over time to determine possible causes, optimal treatment, and survivorship of NHL.

**PARTICIPATION**

Am I Eligible to Participate?

- Must be age 18 years and older
- Must join within 6 months of diagnosis date

What Does Participation Mean?

- Provide written consent
- Provide a blood sample at enrollment
- Complete questionnaires at enrollment and during follow-up
- Grant access to your medical records and pathology samples
- Additional blood samples may also be collected during routine blood draws.

**WHAT IS LEO?**

The Lymphoma Epidemiology of Outcomes (LEO) Study is a collaboration between 8 prominent medical centers and universities around the United States. The goal is to build a large and diverse observational cohort to support a broad research agenda aimed at identifying several factors that impact non-Hodgkin lymphoma survivorship.

We will be collecting data and samples that will help us understand the causes for different types of non-Hodgkin lymphomas, the best treatments and the best ways to help survivors. Your participation in this study is key to our success.